Search

Displaying results 5901 - 5910 of 10000 in total
  1. Drug

    HSV-2 theracine

    go.drugbank.com/drugs/DB05811
    Experimental

    HSV-2 theracine is an attenuated recombinant vaccine developed by AuRx for the treatment of genital herpes.

  2. Drug

    Davalintide

    go.drugbank.com/drugs/DB14956
    Investigational

    Davalintide is under investigation in clinical trial NCT00785408 (Study to Examine Safety, Tolerability and Effect on Body Weight of Subcutaneous AC2307 in Obese or Overweight Subjects).

  3. Drug

    Dubermatinib

    go.drugbank.com/drugs/DB15187
    Investigational

    Dubermatinib is under investigation in clinical trial NCT03572634 (Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL).

  4. Drug

    MK-8189

    go.drugbank.com/drugs/DB19153
    Investigational

    MK-8189 is under investigation in clinical trial NCT04624243 (Efficacy and Safety of MK-8189 in Participants With an Acute Episode of Schizophrenia (MK-8189-008)).

    Synonyms: 4-PYRIMIDINAMINE, 2-METHYL-6-(((1S,2S)-2-(5-METHYL-2-PYRIDINYL)CYCLOPROPYL)METHOXY)-N-((5-METHYL-1,3,4-THIADIAZOL-2-YL)METHYL)-
  5. Drug

    Rebastinib

    go.drugbank.com/drugs/DB13005
    Investigational

    Rebastinib has been used in trials studying the treatment of Chronic Myeloid Leukemia. It is an inhibitor of Tie2 tyrosine kinase receptor and an antineoplastic agent.

  6. Drug

    R112

    go.drugbank.com/drugs/DB06252
    Experimental

    R112 is an investigational compound developed to treat Allergic Rhinitis. It's mechanism of action is to inhibit SYK kinase.

  7. Drug

    TPI-ASM8

    go.drugbank.com/drugs/DB05572
    Investigational

    TPI-ASM8 was under investigation in clinical trials NCT00822861, NCT01158898, NCT00402948, and NCT00550797, all for the treatment of Asthma.

  8. Drug

    Verubecestat

    go.drugbank.com/drugs/DB12285
    Investigational

    In the study, administration of Verubecestat at doses of 12, 40 and 60 mg resulted in a dose-dependent and sustained reduction in the levels of Ab40, a measure of BACE1 activity, in CSF from baseline of … In July 2013, Merck announced positive results for Phase Ib trials of Verubecestat.

  9. Drug

    OT-551

    go.drugbank.com/drugs/DB05650
    Investigational

    OT-551 is a novel small molecule that is topically dosed in an eye drop and has the unique ability to penetrate cell membranes and reach both the front and the back of the eye.

  10. Drug

    APT3111

    go.drugbank.com/drugs/DB06390
    Experimental

    APT3111 is an investigational drug used to treat PNH (paroxysmal nocturnal haemoglobinurea).